Key statistics
As of last trade Harrow Inc (HROW:NMQ) traded at 43.02, -27.37% below its 52-week high of 59.23, set on Oct 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 44.17 |
---|---|
High | 44.45 |
Low | 42.73 |
Bid | 42.88 |
Offer | 43.08 |
Previous close | 43.88 |
Average volume | 955.78k |
---|---|
Shares outstanding | 35.48m |
Free float | 30.46m |
P/E (TTM) | -- |
Market cap | 1.56bn USD |
EPS (TTM) | -0.9408 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 16:36 GMT.
More ▼
- Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
- Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
- Harrow Announces Participation in Upcoming Investor Conferences
- Harrow Announces Third Quarter 2024 Financial Results
- Harrow Launches Access and Affordability Program with Price Reductions for Branded Products
- Harrow Announces Market Access Wins for VEVYE®
- Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products
- Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024
- Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
- Harrow Relaunches TRIESENCE®
More ▼